Earnings Feed
Start Free
Contineum Therapeutics, Inc.·4

Jan 30, 4:52 PM ET

Watkins Tim 4

Research Summary

AI-generated summary

Updated

Contineum (CTNM) CMO Tim Watkins Exercises Options & Sells Shares

What Happened

  • Tim Watkins, Chief Medical Officer & Head of Development at Contineum Therapeutics (CTNM), exercised 3,611 option shares on Jan 28, 2026 at $4.50 per share (cost = $16,250) and sold those 3,611 shares in open-market trades the same day for aggregate proceeds of about $51,188. The filing also reports a grant/award of 160,000 derivative shares on Jan 30, 2026 (no cash price reported).
  • The exercise + sale resulted in gross sale proceeds ~ $51,188 and an approximate spread (proceeds minus exercise cost) of $34,938 before taxes and fees. The 160,000-share award appears to be an equity grant (derivative) subject to vesting.

Key Details

  • Transaction dates: Jan 28, 2026 (exercise and sales); Jan 30, 2026 (award/grant).
  • Exercise: 3,611 shares @ $4.50 (total cost $16,250).
  • Sales: 2,800 shares @ weighted avg $14.09 (proceeds $39,441; prices ranged $13.44–$14.39 per F2); 811 shares @ weighted avg $14.48 (proceeds $11,747; prices ranged $14.45–$14.53 per F3). Total sale proceeds ≈ $51,188.
  • Award/Grant: 160,000 derivative shares reported 1/30/2026 at $0.00 (Form shows as acquisition of derivative).
  • Vesting notes: prior option vesting schedule noted — one-half vested Oct 28, 2025 with remainder vesting monthly (F4); options under the issuer’s 2024 Equity Incentive Plan vest over 48 months (F5).
  • Sales were effected under a pre-established 10b5-1 trading plan adopted Sept 23, 2025 (F1).
  • Shares owned after the transactions: not specified in the provided filing excerpt.
  • Filing timeliness: Form filed Jan 30, 2026 for transactions on Jan 28, 2026 — within the usual 2-business-day Form 4 reporting window (not marked late).

Context

  • This was a routine executive option exercise followed by open-market sales (common for option liquidity or tax/portfolio management). The sale was conducted under a 10b5-1 plan, which typically schedules trades in advance. The 160,000-share derivative award is subject to vesting per the plan footnotes; such grants are compensation, not an open-market purchase signal.